EpiThany is dedicated to the advancement of innovative therapies that can improve the lives of cancer patients. Our focus is on developing tumor vaccines that drive
Th1 (tumor-eradicating) immune responses without
stimulating competitive Th2 (tumor-tolerant) responses.
EpiThany technology enables the targeting of myriad tumor antigens
across a spectrum of cancers, yielding a deep pipeline of Th1-selective anti-cancer vaccines.